Protagenic Therapeutics Statistics
Share Statistics
Protagenic Therapeutics has 252.48M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 252.48M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | -% |
Short Selling Information
The latest short interest is 0, so 0% of the outstanding shares have been sold short.
| Short Interest | 0 |
| Short % of Shares Out | 0% |
| Short % of Float | 0% |
| Short Ratio (days to cover) | 0 |
Valuation Ratios
The PE ratio is -0.86 and the forward PE ratio is null.
| PE Ratio | -0.86 |
| Forward PE | null |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.17 |
| P/FCF Ratio | -1.12 |
| PEG Ratio | n/a |
Enterprise Valuation
Protagenic Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 6.41, with a Debt / Equity ratio of 0.
| Current Ratio | 6.41 |
| Quick Ratio | 6.41 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.36% and return on capital (ROIC) is -123.41%.
| Return on Equity (ROE) | -1.36% |
| Return on Assets (ROA) | -1.16% |
| Return on Capital (ROIC) | -123.41% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -5.00M |
| Employee Count | 1 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0.25, so Protagenic Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.25 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.03 |
| Relative Strength Index (RSI) | 53.53 |
| Average Volume (20 Days) | - |
Income Statement
In the last 12 months, Protagenic Therapeutics had revenue of $0 and earned -$5.00M in profits. Earnings per share was $-1.15.
| Revenue | 0 |
| Gross Profit | -28.22K |
| Operating Income | -4.53M |
| Net Income | -5.00M |
| EBITDA | -4.50M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.15 |
Balance Sheet
The company has $1.29M in cash and $0 in debt, giving a net cash position of $1.29M.
| Cash & Cash Equivalents | 1.29M |
| Total Debt | 0 |
| Net Cash | 1.29M |
| Retained Earnings | -30.78M |
| Total Assets | 1.51M |
| Working Capital | 633.39K |
Cash Flow
In the last 12 months, operating cash flow was -$3.70M and capital expenditures -$149.78K, giving a free cash flow of -$3.85M.
| Operating Cash Flow | -3.70M |
| Capital Expenditures | -149.78K |
| Free Cash Flow | -3.85M |
| FCF Per Share | -0.89 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
PTIXW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for PTIXW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -41.26 |
| Piotroski F-Score | 3 |